Abstract
This study evaluated the effects on bone mineral status of long-term treatment with intranasal budesonide (INB) spray, using the recommended dose, in pediatric patients with allergic rhinitis (AR). This retrospective, case–control study of 230 prepubertal children with perennial AR, who had used nasal budesonide at a mean daily dose of 100 μg (range, 89–132 μg) for at least 3 years intermittently, was conducted from May 2007 through May 2010. The bone mineral density (BMD) of the lumbar spine was measured by dual-energy X-ray absorptiometry. Levels of serum calcium, phosphorus, alkaline phosphatase (ALP), parathyroid hormone, and osteocalcin were also assessed. The results were compared to sex- and age-matched controls (n = 140), who were newly diagnosed children with AR without any corticosteroid treatment. The 230 study patients (145 boys) were aged from 7 to 11 years. The average age (± SEM) was 8.7 ± 0.7 years; the mean (± SEM) steroid dosage used was 73.5 ± 7.0 μg daily, with 65.2 ± 5.2 g total steroid use during treatment. The 140 control patients (90 boys) were aged from 6 to 11 years. No significant differences were observed in BMD (P > 0.05) between the study and the control groups. Although mean serum ALP level was higher, and cortisol, phosphorus, and osteocalcin levels were lower, in the treatment group, these differences were not statistically significant. The findings suggest that long-term intermittent treatment for 3 years with INB spray, 50 μg twice daily, for children with perennial rhinitis revealed no negative effect on BMD and associated parameters.
Similar content being viewed by others
References
Skoner DP (2001) Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 108:S2–S8
Ibiapina Cda C, Sarinho ES, Camargos PA, Andrade CR, Cruz Filho AA (2008) Allergic rhinitis: epidemiological aspects, diagnosis and treatment. J Bras Pneumol 34:230–240
Bloebaum R (2002) Managing allergic rhinitis: the role of pharmacotherapy; sound treatment can improve your patient’s quality of life. J Respir Dis 23:370–376
Blaiss MS (2007) Safety consideration of intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc 28:145–152
Baena-Cagnani CE (2004) Safety and tolerability of treatments for allergic rhinitis in children. Drug Saf 27:883–898
Rizzo MC, Solé D, Naspitz CK (2007) Corticosteroids (inhaled and/or intranasal) in the treatment of respiratory allergy in children: safety vs. efficacy. Allergol Immunopathol (Madr) 35:197–208
Ebeling PR, Erbas B, Hopper JL, Wark JD, Rubinfeld AR (1998) Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J Bone Miner Res 13:1283–1289
Jones A, Fay JK, Burr M et al (2002) Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev 1:CD003537
Altintas DU, Karakoc GB, Can S, Yilmaz M, Kendirli SG (2005) The effects of long term use of inhaled corticosteroids on linear growth, adrenal function and bone mineral density in children. Allergol Immunopathol 33:204–209
Skoner DP, Rachelefsky GS, Meltzer EO et al (2000) Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 105:E23
Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A et al (2000) Absence of growth retardation in children with perennial allergic rhinitis after one-year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 105:E22
Murph K, Uryniak T, Simpson B, O’Dowd L (2006) Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Ann Allergy Asthma Immunol 96:723–730
Möller C, Ahlström H, Henricson KÅ, Malmqvist LÅ, Åkerlund A, Hildebrand H (2003) Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 33:816–822
Brozek JL, Baena-Cagnani CE, Bonini S et al (2008) Methodology for development of the Allergic Rhinitis and Its Impact on Asthma Guideline 2008 update. Allergy 63:38–46
Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J et al (1999) Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 10:259–264
Baim S, Leonard MB, Bianchi ML, Hans DB, Kalkwarf HJ, Langman CB, Rauch F (2008) Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom Assess Skelet Health 11:6–21
Passalacqua G, Albano M, Canonica GW et al (2000) Inhaled and nasal corticosteroids: safety aspects. Allergy 55:16–33
Juniper EF, Stahl E, Doty RL et al (2005) Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol 115:S390–S413
Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Prestwood K, Frieri M et al (2005) Use of oral corticosteroids and risk of features. J Bone Miner Res 20:1487–1494
Bielory L, Blaiss M, Fineman SM, Ledford DK, Lieberman P, Simons FE et al (2006) Concerns about intranasal corticosteroids for over-the-counter use: position statement of the Joint Task Force for the American Academy of Allergy, Asthma and immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 96:1–12
Martinati LC, Bertoldo F, Gasperi E, Fortunati P, Lo Cascio V, Boner AL (1998) Longitudinal evaluation of bone mass in asthmatic children with inhaled beclomethasone dipropionate or cromolyn sodium. Allergy 53:705–708
Mainz JG, Sauner D, Malich A, John S, Beyermann H, Mentzel HJ et al (2008) Cross-sectional study on bone density related sonographic parameters in children with asthma: correlation to therapy with inhaled corticosteroids and disease severity. J Bone Miner Metab 26:485–492
Allen HD, Thong IG, Clifton-Blight P, Holmes S, Nery L, Wilson KB (2000) Effects of high-dose inhaled corticosteroids on bone metabolism in prepubertal children with asthma. Pediatr Pulmonol 29:188–193
Wilson AM, Sims EJ, Mc Farlane LC, Lipworth BJ (1998) Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic-rhinitis. J Allergy Clin Immunol 102:598–604
Sheth K (2008) Evaulating the safety of intranasal steroids in the treatment of allergic rhinitis. Allergy Asthma Clini Immunol 4:125–129
Akil I, Yuksel H, Urk V, Onur E, Var A, Guvenc Y (2003) Biochemical markers of bone metabolism and renal calcium excreation in the asthmatic patient treated with inhaled corticosteroids. Asthma Allergy Immunol (Turkish) 1:5–10
Reilly SM, Hambleton G, Adams JE, Mughal MZ (2001) Bone density in asthmatic children terated with inhaled corticosteroids. Arch Dis Child 84:183–187
Jones CD, Laval-Jeantet AM, Laval-Jeantet MH, Genant HK (1987) Importance of measurement of spongious vertabral bone mineral density in the assessment of osteoporosis. Bone (NY) 8:201–206
Kemp JP, Osur S, Shrewsbury SB, Herje NE, Duke SP, Harding SM et al (2004) Potential effect of fluticasone propionate on bone mineral density in patients with asthma; a 2-year randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 79:458–466
Agertoft L, Pedersen S (1998) Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide. Am J Respir Crit Care 157:178–183
Johnston CC, Miller JZ, Slemenda CW (1992) Calcium supplementation and increase in bone mineral density in children. N Engl J Med 327:82–87
Gagnon L, Boulet LP, Brown J, Desrosiers T (1997) Influence of inhaled corticosteroids and dietary intake on bone density and metabolism in patients with moderate to severe asthma. J Am Diet Assoc 97:1401–1406
Acknowledgments
The authors have no financial or personal relationships with other persons or organizations that could pose a conflict of interest in connection with the present work.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Emin, O., Fatih, M., Emre, D. et al. Lack of bone metabolism side effects after 3 years of nasal topical steroids in children with allergic rhinitis. J Bone Miner Metab 29, 582–587 (2011). https://doi.org/10.1007/s00774-010-0255-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00774-010-0255-3